Trial Profile
Fluzoparib Combined With Apatinib for the Treatment of Carrying TP53 Harmful Mutations in Advanced Refractory Solid Tumors of the I Stage Clinical Study
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Fuzuloparib (Primary) ; Rivoceranib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 24 Apr 2019 Planned initiation date changed from 1 Sep 2018 to 1 Jul 2019.
- 31 Aug 2018 New trial record